Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors

Mast cell tumor (MCT) is the most common cutaneous neoplasm in dogs and wide surgical resection is the current first-line treatment. However, recurrence is common and often requires more specialist and expensive therapies. Tigilanol tiglate is a novel small molecule drug delivered by intratumoral in...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Jane, Campbell, Justine, Blum, Andrew, Reddell, Paul, Gordon, Victoria, Schmidt, Peter, Lowden, Stewart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Veterinary Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499228/
https://www.ncbi.nlm.nih.gov/pubmed/31111038
http://dx.doi.org/10.3389/fvets.2019.00106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499228/
https://www.ncbi.nlm.nih.gov/pubmed/31111038
http://dx.doi.org/10.3389/fvets.2019.00106

Ejemplares similares